Shares of biopharma company Alexion (ALXN) opened up 7% when market started today after it reported a rise in Q1 2018 earnings and revenue, and lifted the guidance for the year. Along with this, the company also reported a positive top line results for its Phase 3 study.
The company that specializes in manufacturing drugs for rare disorder reported a 7% increase in its revenue to $930.9 million. Earnings per share rose 48% to $1.11 and excluding items, the company’s earnings per share rose 22% during the quarter.
Net product sales of the key drug Soliris, which accounts for a bulk of the company’s revenue and is used to treat serious genetic-based blood condition, grew 2% during the quarter to $800.1 million.
Alexion has been working aggressively on rebuilding its pipeline. This is one of the reasons why it recently acquired Wilson Therapeutics based in Sweden. This deal, valued at $855 million, gives Alexion a greater control over the Wilson’s rare disease drug WTX101. Also, this new drug will reduce the company’s complete dependence on Soliris for generating revenue. The transaction is expected to close during the second quarter of this year.
The drugmaker also reported positive topline results for its Phase 3 study that is again used to treat a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH).
The company also raised its guidance for revenue and adjusted EPS for the full year. Alexion now expects its revenue to be in the range of about $3.93 to 3.99 billion, up from the previous estimate of $3.85 to $3.95 billion and adjusted EPS to be about $6.75 to $6.90, up from the prior estimate of $6.60 to $6.80.
Today, apart from Alexion, two other drugmakers reported their results before the market opened. While AbbVie (ABBV) reported strong results and trades in the positive territory, Bristol-Myers Squibb (BMY) shares were down 1% in the morning session. Vertex Pharmaceuticals (VRTX) will announce its quarterly results after the market closes today.
Most Popular
Take-Two Interactive Software (TTWO) Earnings: 4Q24 Key Numbers
Take-Two Interactive Software, Inc. (NASDAQ: TTWO) reported net revenue of $1.40 billion for the fourth quarter of 2024, which was down 3% year-over-year. Net loss was $2.90 billion, or $17.02
Applied Materials (AMAT) Earnings: 2Q24 Key Numbers
Applied Materials, Inc. (NASDAQ: AMAT) reported revenue of $6.65 billion for the second quarter of 2024, which remained flat year-over-year. GAAP net income increased 9% to $1.72 billion and EPS
What to expect when Macy’s (M) reports its Q1 2024 earnings results
Shares of Macy’s, Inc. (NYSE: M) stayed green on Thursday. The stock has gained 23% over the past 12 months. The retailer is scheduled to report its first quarter 2024
